The global infertility drugs market is set for significant growth over the next decade, with the market size valued at USD 3,699.8 million in 2023. According to industry analysis, the market is projected to expand at a compound annual growth rate (CAGR) of 6.3%, reaching USD 6,814.68 million by 2033.
Infertility, which affects both men and women equally, is becoming a growing concern globally. The increasing prevalence of infertility, driven by factors such as delayed pregnancies, lifestyle changes, and underlying health conditions, is expected to drive the demand for infertility drugs over the forecast period.
Key Market Drivers:
- Rising Infertility Rates: The increasing incidence of infertility among both women and men is a major factor fueling the demand for infertility drugs. Factors like lifestyle changes, stress, and health issues are contributing to this rise.
- Advancements in Fertility Treatments: Ongoing research and development efforts in fertility treatments, including more effective and accessible infertility drugs, are boosting the market.
- Increasing Awareness and Access to Treatment: Growing awareness of infertility treatment options and improved access to fertility care across the globe are further supporting market growth.
Regional Insights: North America is expected to dominate the infertility drugs market due to the high prevalence of infertility, advanced healthcare infrastructure, and strong investment in fertility treatment research. Europe is anticipated to follow closely, while the Asia-Pacific region is emerging as a key growth area, driven by improving healthcare access and rising awareness of fertility treatments in countries such as India and China.
Market Outlook: As the demand for effective fertility treatments continues to rise, the global infertility drugs market is poised for robust growth over the coming decade. Advances in drug development, coupled with greater access to treatment options and increasing awareness about infertility, are expected to drive market expansion through 2033.
For treating infertility, market players are introducing novel medications. In the current instance, Oxolife is developing the first-in-class product candidate OXO-001, which is designed to enhance the binding of embryos to the inner lining of the uterus by increasing binding. Moreover, the United States-based biopharmaceutical company Ferring Pharmaceuticals recently launched its novel fertility treatment, Trisequens, for women.
Developing such products addresses a medical need that affects women around the world undergoing assisted reproduction because there is no substitute for improving the endometrium’s conditions for embryo implantation.
Infertility medicines are expected to contribute positively to the market as well as the presence of a variety of products for treating these conditions. For example, In-vitro fertilization (IVF) treatments, which involve fertilizing an egg outside of the body, are becoming more commonplace and are expected to drive market growth.
Infertility problems are caused by hormonal imbalance, polycystic ovarian disease, and weight issues caused by sedentary lifestyles. Therefore, the market is likely to grow over the forecast period as sedentary lifestyles become increasingly popular. The market growth may likely be hindered by rigid regulatory frameworks for product approval and high-priced patented products.
Competitive Landscape: Key Players Operating in the Global Infertility Drugs Market
Several key players dominate the global infertility drugs market, which is moderately competitive. A competitive landscape analysis includes some international and local companies that hold the market share and are well known, such as Ferring Pharmaceuticals Inc., Merck KGaA, Bayer AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Theramex, and Novartis AG.
- Abbott Laboratories
- Bayer AG, Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Ferring Holdings SA
- Organon & Co.
- Mankind Pharma Ltd.
Recent Development
The strategy of mergers, acquisitions, investments, expansions of capacity, and plant turnarounds by major manufacturers, is further strengthening the market player presence and helping them in staying ahead of the competition.
- For fertility treatment in India, Merck launched the Pergoveris Pen in August 2021. With the Pergoveris Pen, recombinant follicle-stimulating hormone and recombinant luteinizing hormone are combined in a ready-to-use device that an IVF specialist can prescribe. By combining bulk technology with a globally approved pen, infertile couples can provide themselves with a safe self-service infertility solution.
- The AI-powered insurance platform InsurMedix closed a US$ 65 million funding round in November 2021 to cover fertility treatments. As the platform launched in the United States in early 2022, it provides fertility insurance, including IVF, complementary and alternative medicine, as well as medical tourism.
- With Hamilton Thorne’s partnership in 2020, Genea Biomedx (Australia) planned to sell its fertility products in the United States and Canada. Genea Biomedx will be distributing Hamilton Thorne’s IVF laboratory systems, including their flagship product, the ZILOS-tk™ Workstation.
- Pergoveris Pen was introduced by Merck to India in August 2021 to treat infertility. It is the first pen injector for gonadotropins, which are hormones that play an important role in fertility and reproduction.
- Maven Clinic recently announced a partnership with The Fertility Partners, the prominent provider of fertility services in Canada, as part of its fertility clinic referral network. This network supports Maven’s members in more than 70 countries in finding high-quality fertility care. Additionally, Maven launched MavenRx, a new medication service, in February 2020 to help fertility members more seamlessly get their medications.
Key Companies Profiled
Abbott Laboratories;
Bayer AG, Novartis AG;
Merck & Co., Inc.;
Pfizer, Inc.;
Teva Pharmaceuticals Industries Ltd.;
Sanofi S.A.;
Ferring Holdings SA;
Organon & Co.;
Mankind Pharma Ltd.
Infertility Drugs Market Segmentation by Category
By Drug Class:
- Gonadotrophins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Biguanides
- Other Drug Classes
By End User:
- Male
- Female
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Other Distribution Channels
By Region Outlook:
- North America
- Latin America
- Europe
- The Middle East and Africa
- East Asia
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube